Adaptive Radiation Boost for Prostate or Bladder Cancer
Tests an adaptive radiation boost in adults with prostate or bladder cancer.
Plain-language title generated from the registry record
Registry title: Adaptive Radiotherapy for Genitourinary Cancers
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Cancer Hospital, National Cancer Center, CAMS & PUMCBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Trial code
- NCT07324798
- Record updated
- 7 January 2026
- Original description
The goal of this clinical trial is to learn if adaptive radiation boost works to treat genitourinary cancers, esp. in the context of prostate cancer patients with post-prostatectomy local relapse and bladder cancer patients with bladder-conserving treatment. It will also learn about the safety and efficacy of adaptive boost. The main questions it aims to answer are:Read full original descriptionShow less
Prospective Study of siMultaneous Adaptive RadioTherapy for Local Boost for Prostate and Bladder Cancers (SMART-B01)
The goal of this clinical trial is to learn if adaptive radiation boost works to treat genitourinary cancers, esp. in the context of prostate cancer patients with post-prostatectomy local relapse and bladder cancer patients with bladder-conserving treatment. It will also learn about the safety and efficacy of adaptive boost. The main questions it aims to answer are:
Does adaptive boost lower the toxicities? Does adaptive boost maintain or improve the clinical efficacy?
Participants will:
Undergo adaptive boost on 1.5-Tesla MR-Linac Visit the clinic once every 2 weeks during RT, and every 3 months post-ART Keep a regular QOL questinnaire completion
Inclusion: Patients with newly diagnosed or metastatic/recurrent pathologically confirmed urological tumors, clinically assessed as suitable for adaptive radiotherapy; Age ≥ 18 years; ECOG performance status score 0-2; No prior radiotherapy history within the current radiation field; No contraindications for MRI scanning; No contraindications for radiotherapy.
Exclusion: Patients with contraindications to radiotherapy; Patients unable to tolerate MRI or with contraindications to MRI scanning.